OUR COVID-19 VACCINE IS OVER 90% EFFECTIVE – PFIZER AND BIONTECH SAYS
Pfizer Inc on Monday, November 9, said its experimental vaccine is 90% effective in preventing COVID-19 based on initial data from a large study.
This development means that Pfizer and German partner, BioNTech SE BNTX.O, are the first drug makers to show successful data from a large-scale clinical trial of a Coronavirus vaccine.
The companies, in a statement on Monday, said they have so far found no side effects and concerns with the drug, and expect to seek the U.S. authorization later this month.
“Today is a great day for science and humanity. We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” Albert Bourla, Pfizer’s chairman and chief Executive said.
It is expected that Pfizer would seek U.S. emergency use authorization of the vaccine for people aged 16 to 85.
Read Also: US POLITICIAN WHO DIED OF COVID-19 WINS LEGISLATIVE SEAT IN NORTH DAKOTA
“I’m near ecstatic, this is a great day for public health and for the potential to get us all out of the circumstances we’re now in,” Bill Gruber, one of Pfizer’s top vaccine scientists, said in an interview.
The efficacy of this vaccine is a major victory in the fight against the Coronavirus pandemic that has killed over 1 million people globally, and has crumbled the world's economy.
Pfizer Inc. is an American multinational pharmaceutical corporation headquartered in New York City.
In 2012, it was one of the world's largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.
Read Also: COVID:19 - SIX TEST POSITIVE FOR COVID-19 IN LAGOS SECONDARY SCHOOL
Comments